• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>Bristol-Myers Squibb

Bristol-Myers Squibb

Bristol-Myers Squibb Company BMY

Last Price$71.31Day Change (%)0.82%
Open Price$70.94Day Change ($)0.58
Day Range70.71–71.5452-Week Range51.82–73.06

As of Fri 5/27/2016 6:07:00 PM | USD

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  6. Research
  1. New Hope for Melanoma Patients -- Update

    New Hope for Melanoma Patients -- Update

  2. Oncodesign is Granted New Patent Protecting Key Molecules Generated from Its Nanocyclix Technology Platform for Next Generation Kinase Inhibitors

    Oncodesign is Granted New Patent Protecting Key Molecules Generated from Its Nanocyclix Technology Platform for Next Generation Kinase Inhibitors

  3. Global Myocardial Infarction Treatment Market Growth of 3.1% CAGR by 2025 - Analysis, Technologies & Forecasts Report 2016-2025 - Key Vendors: Bayer, Pfizer, Mylan - Research and Markets

    Global Myocardial Infarction Treatment Market Growth of 3.1% CAGR by 2025 - Analysis, Technologies & Forecasts Report 2016-2025 - Key Vendors: Bayer, Pfizer, Mylan - Research and Markets

  4. UPDATE: Four reasons for investors to buy biotechnology stocks now

    UPDATE: Four reasons for investors to buy biotechnology stocks now

  5. Allied Minds Announces Successful Completion of ABLS II Drug Candidate Feasibility Program and Approval of Up to $15 Million to Fund Further Drug Development

    Allied Minds Announces Successful Completion of ABLS II Drug Candidate Feasibility Program and Approval of Up to $15 Million to Fund Further Drug Development

  6. Opdivo® (nivolumab) Granted First Approval of a PD-1 Inhibitor in Hematology for the Treatment of Classical Hodgkin Lymphoma Patients Who Have Relapsed or Progressed After Auto-HSCT and ...

    Opdivo® (nivolumab) Granted First Approval of a PD-1 Inhibitor in Hematology for the Treatment of Classical Hodgkin Lymphoma Patients Who Have Relapsed or Progressed After Auto-HSCT and Post-transplantation Brentuximab Vedotin by the FDA1

  7. Nordic Nanovector ASA: New Board Members Elected Bringing Further Expertise in the Development and Commercialization of Innovative Cancer Therapies

    Nordic Nanovector ASA: New Board Members Elected Bringing Further Expertise in the Development and Commercialization of Innovative Cancer Therapies

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.